Global Cell & Gene Therapy Bioanalytical Testing Services Market Gains Momentum with Regulatory Advancements
The cell & gene therapy bioanalytical testing services market size was valued at USD 579.30 million in 2025.The market is anticipated to grow from USD 620.75 million in 2026 to USD 1091.86 million by 2034, exhibiting a CAGR of 7.30% during 2026–2034. This growth is driven by the increasing demand for advanced therapeutic modalities and the need for rigorous testing services to ensure the safety and efficacy of these therapies. North America and Europe are leading the market, owing to their robust healthcare infrastructure, substantial investments in research and development, and supportive regulatory environments.
In North America, particularly the United States, the market is experiencing significant growth due to the presence of major pharmaceutical and biotechnology companies, coupled with substantial funding for cell and gene therapy research. The U.S. Food and Drug Administration's (FDA) expedited approval processes for innovative therapies have further accelerated market expansion. Additionally, the establishment of specialized testing laboratories and centers of excellence in gene therapy has bolstered the region's capabilities in bioanalytical testing services.
Europe follows closely, with countries like Germany, France, and the United Kingdom investing heavily in biotechnology and life sciences. The European Medicines Agency (EMA) has implemented favorable regulatory frameworks that facilitate the development and approval of gene therapies, thereby driving the demand for bioanalytical testing services. Moreover, cross-border collaborations and partnerships among academic institutions, research organizations, and industry players have enhanced the region's research capabilities and service offerings.
Asia Pacific is emerging as a significant market for cell & gene therapy bioanalytical testing services, driven by increasing healthcare expenditures, advancements in biotechnology, and growing clinical trial activities. Countries such as China and India are witnessing a surge in the number of clinical trials, necessitating the expansion of testing services to meet regulatory requirements. The region's large patient population and rising prevalence of chronic diseases further contribute to the demand for innovative therapies and associated testing services.
The competitive landscape of the market is characterized by the presence of both established players and emerging companies offering specialized testing services. Key players in the market include BioAgilytix Labs, KCAS Bioanalytical Services, and IQVIA, Inc. These companies are focusing on expanding their service portfolios, enhancing testing capabilities, and forming strategic partnerships to strengthen their market
More Trending Latest Reports By Polaris Market Research:
Induced Pluripotent Stem Cell (Ipsc) Market
Hospital Electronic Health Records Market
positions.
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek